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Abstract: 
Due to high cervical cancer rates and limited research on human papillomavirus (HPV) vaccine 
acceptability in India, the research team examined parental attitudes toward HPV vaccines. 
Thirty-six interviews with parents were conducted to assess sexually transmitted infection (STI)-
related knowledge and HPV-specific vaccine awareness and acceptability. Despite limited 
knowledge, parents had positive views toward HPV vaccines. Common barriers included 
concerns about side effects, vaccine cost, and missing work to receive the vaccine. Parents were 
strongly influenced by health care providers’ recommendations. Our findings suggest that 
addressing parental concerns, health worker training and polices, and efforts to minimize cost 
will be central to successful HPV vaccine implementation. 
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Article: 
Cervical cancer is the most common cancer among Indian women, closely followed by breast 
cancer. In 2008, age-standardized incidence and mortality rate estimates cervical cancer in India 
were 27.0 and 15.2 per 100,000 women, respectively, which is considerably higher compared 
with the global estimates (15.2 and 7.8 per 100,000 women; Ferlay et al., 2008; [Globocan, 
2008]). Nearly 60% of high-grade lesions and 80% of cervical cancers are due to HPV-16 and 
HPV-18. Organized cervical cancer screening programs have significantly reduced cervical 
cancer rates in developed countries. Although the National Cancer Program in India supports 
early screening and treatment of cervical cancer, implementations of screening programs are 
inadequate or nonexistent due to logistical barriers such as insufficiently trained staff and 
infrastructure (Bharadwaj, Hussain, Nasare, & Das, 2009). 
Vaccinating against HPV infection, therefore, is a promising additional strategy for reducing 
cervical cancer rates. Vaccination may be especially relevant in India, home to one-fifth of the 
worldwide cervical cancer burden, which represents the largest burden in the world (Jemal et al., 
2011; Sankaranarayanan, Budukh, & Rajkumar, 2001) and where screening programs are 
inadequate (Dabash et al., 2005). In 2008, the Indian Academy of Pediatrics Committee of 
Immunization, along with the Federation of Obstetric and Gynaecological Societies of India, and 
the WHO Strategic Advisory Group of Experts on Immunization, recommended HPV vaccine 
for 10–12-year-old females, with catch-up vaccination through age 26 (IAPCOI, 2008). The 
public health sector supports a childhood immunization program, which provides the Expanded 
Program on Immunization (EPI) in India for free, but other vaccines, like HPV vaccines, are 
solely available for purchase through the private sector. Compared with younger children, 
adolescents are traditionally underserved by India's health care system (Kumar, Prinja, & 
Lakshmi, 2008; Nath & Garg, 2008). In addition to parents (Bharadwaj et al., 2009; Das, 
Hussain, Nasare, & Bharadwaj, 2008), community perceptions, political will, provider support, 
and innovative delivery strategies will be important for acceptance and sustainability of HPV 
vaccination and adding the vaccine into the EPI schedule in India. 
The context for HPV vaccination has been described in the developed (Brewer & Fazekas, 2007; 
Zimet et al., 2006; Zimet, Shew, & Kahn, 2008) and developing (specifically Asia) world (Basu 
& Mittal, 2011; Bingham, Drake, & Lamontagne, 2009; Dinh et al., 2007; Jacob et al., 2010; 
Kwan et al., 2008; Madhivan et al., 2009; Sam et al., 2009). A review of these studies indicates 
that government endorsement, cancer prevention, confidence in immunizations, and provider's 
recommendation are factors in vaccine acceptance. Major obstacles to acceptance are high cost 
and fear of side effects. There have been a few studies targeting parents in India (Basu & Mittal, 
2011; Bingham et al., 2009; Jacob et al., 2010; Madhivanan et al., 2009). These researchers 
suggest a relatively positive response to vaccinating 9–15 year olds. 
Understanding HPV vaccine acceptability in India is crucial given the enormous cultural, 
religious, and ethnic diversity and that relatively little research has been done in India (for 
exceptions see Basu & Mittal, 2011; Bingham, Janmohamed, et al., 2009; Jacob et al., 2010; 
Madhivan et al., 2009) compared with the extensive research done in England, Australia, and the 
United States (all much smaller countries with lower cervical cancer burden; Brewer & Fazekas, 
2007; Zimet, Liddon, Rosenthal, Lazcano-Ponce, & Allen, 2006; Zimet, Shew, & Kahn, 2008). 
Since social practices in India not only differ from other countries, but also significantly differ 
across states and geographical regions, the purpose of this study was to use qualitative research 
methods to examine parental, particularly mothers’, attitudes about HPV vaccine prior to its 
availability in perirural areas outside of Hyderabad, India. 
METHODS 
Study Design and Population 
Parents were recruited in 2008 from Medchal Mandal and Shamirpet Mandal, Andhra Pradesh, 
India. The local private hospital is involved in community-based activities, including a 
population-based cervical cancer screening study, the Community Access to Cervical Health 
(CATCH) Study (Gravitt et al., 2010). Villages in Medchal were selected based on their CATCH 
Study participation rates. Villages screening more than 45% of the population were considered 
high participation; villages screening under 45% were considered low. Three villages from both 
categories were purposively selected. In Shamirpet, with no active cervical cancer prevention 
activities, three villages were randomly selected. The Institutional Review Boards in India 
(SHARE India/MediCiti Institute of Medical Sciences) and the United States (Johns Hopkins 
University Bloomberg School of Public Health) approved the protocol. 
A list of eligible mothers (with daughter(s) under 18 years old) in Medchal was generated using 
the hospital's computerized census database. Interviewers went to the house of every tenth 
person on the list and invited the mother (or father) to participate until topical saturation was 
reached. In Shamirpet, a convenience sample of 2–4 eligible parents were selected from each 
village. Thirty-six interviews were completed, including 20 mothers from Medchal (10 high 
participation, 10 low participation) and 10 from Shamirpet; 6 fathers were interviewed from 
Medchal Mandal. Participation was voluntary, and no incentive was provided. 
Data Collection 
After slight modifications for cultural appropriateness, a semi structured interview guide from a 
U.S. study (Mays, Zimet, Winston, Kee, Dickes, & Su, 2000; Mays, Sturm, & Zimet, 2004) was 
used. The guide was translated into the local language of Telugu and back translated into 
English. The interviews were conducted in Telugu; informed consent was obtained orally from 
all participants. 
Individual interviews explored the sociocultural environment and current vaccine infrastructure 
in Andhra Pradesh, India, with respect to (a) current vaccine utilization (e.g., Have your children 
received vaccines through the EPI program? What vaccines have they received?), (b) potential 
barriers to receiving existing and new vaccine (e.g., What are reason for not getting vaccines?), 
(c) knowledge of HPV and related diseases (e.g., What do you know about HPV? What are the 
potential outcomes related to HPV?), and (d) attitudes toward HPV immunization (e.g., Do you 
think an HPV vaccine is needed? At what age would you be willing to vaccinate your child for 
HPV?). Participants were asked about the current immunization programs and vaccine 
availability. Next, participants’ knowledge regarding HPV infection, genital warts, and cervical 
cancer was assessed. Since pilot testing of the guide indicated very limited knowledge about 
HPV and HPV-related diseases, a script was developed to provide medically accurate 
information on HPV, HPV vaccine, and cervical cancer so participants could provide their 
opinions on HPV-vaccines. The interviewer verbally provided this information to every 
participant before eliciting opinions about HPV vaccination. Demographic information (e.g., age, 
occupation, education, religion) were collected. 
Data Analysis 
The interviews were audiorecorded, transcribed verbatim, and translated from Telugu into 
English. Prior to the analysis, all personal identifiers were removed. Qualitative data were 
managed using Atlas ti. 6.0 (Muhr, 2004). To analyze the interview data, a coding matrix was 
created based on the literature, interview questions, and preliminary readings of transcripts. 
Following constant comparison methodology, this coding structure was applied to the full 
transcripts and then transcripts, were searched for negative cases to identify exceptions to the 
initial themes; codes were modified as needed, with returns to the data for additional 
comparisons across parents (e.g., by gender; Glaser & Strauss, 1967). Emergent categories 
included the following: (a) STI, HPV, and cervical cancer knowledge; (b) general vaccine 
knowledge and behaviors; and (c) HPV vaccine preferences and acceptability. The researchers 
selected quotes that best represented the themes illustrating the commonalities and individual 
variation among the parents and were edited for readability and clarity. 
RESULTS 
The participants were 19–62 years old (average = 30), and the majority were mothers (83%) and 
Hindu (81%). Education ranged from none to postgraduate degrees, and most (67%) were 
employed. Table 1 provides a complete description of relevant demographic information. 
TABLE 1 Participant Characteristics 
Characteristic  N % 
Age (in years)     
 Mean = 30     
 <25   9 25.0 
 25–34   14 38.9 
 35–44   9 25.0 
 45+   2 5.6 
 DK/not reported 2 5.6 
Gender    
 Female  30 83.3 
 Male   6 16.7 
Religion     
 Hindu   29 80.6 
 Christian  5 13.9 
 Not reported  2 5.6 
Education status     
 None   13 36.1 
 1–8   12 33.3 
 9+   9 25.0 
 Missing  2 5.6 
Occupation     
 Not employed 12 33.3 
 Employed  24 66.7 
Total number of children     
 1   3 8.3 
 2   19 52.8 
 3   10 27.8 
 4+   4 11.1 
Age of eldest daughter (in years)     
 16+   7 19.4 
 9–15   12 33.3 
 <9   13 36.1 
 Missing  4 11.1 
Vaccinated status of EPI vaccines     
 Not vaccinated 4 11.1 
 Vaccinated  21 58.3 
 Don't know  11 30.6 
All children vaccinated through EPI program     
 Yes   35 97.2 
 No   1 2.8 
Knowledge About STI, HPV, and Cervical Cancer 
Parents had low levels of STI awareness with the exception of HIV/AIDS. Nearly all the 
respondents (n = 28) reported HIV/AIDS knowledge with a high level of accurate information: 
“This infection affects people through multiple sexual contacts with unknown persons and also 
through injections” (mother, 35 years old). Conversely, seven participants reported not knowing 
about condoms (nirodh). 
In contrast to high HIV/AIDS knowledge, only two parents reported any knowledge of HPV. All 
but seven participants had heard of cervical cancer; however, only one knew cervical cancer was 
associated with an STI: “Sometimes, some HPV types cause warts in the genital area called 
venereal or genital warts. It gets both in men and women. Sometimes, other HPV types cause 
cervical cancer” (mother, 28). 
General Vaccine Knowledge and Behavior 
Overall, parents understood that vaccinations were important “to have good health, to keep 
children healthy, and prevent disease” (mother, 20), with several parents (n = 7) specifically 
stating that vaccines protect children's health. One mother (28) added: 
For the small children, vaccines are very much needed because, as we are educated, we know the 
importance of vaccines. It is important to give vaccine to children because we've seen children 
who suffered from polio. To avoid getting polio and other diseases, we give these vaccines, to 
better their childhood and then the child will be healthy and safe. 
Despite the awareness of vaccine benefits, understanding was low about specific illnesses that 
vaccines target. While the majority of parents (n = 35) reported their children received complete 
vaccinations, they were less sure about what their children had been vaccinated against. Some 
mentioned diseases such as polio and hepatitis, other parents were uncertain: “I don't know the 
names, but my children they got vaccinated” (mother, 38). Several parents were unaware of need 
for vaccines to be given at older ages: “I don't know, nobody told me [about need to vaccinate at 
5 and 10 years of age]” (mother, 30). Not surprisingly, given that the vaccine was not currently 
available, none of the participants knew about the HPV vaccine. 
Most parents reported having access to the government supported childhood immunization 
program. The program includes a government health worker or auxiliary nurse midwife (ANM 
also called “government sister”) traveling monthly to the villages to provide a variety of 
vaccinations to infants. All program vaccines are provided free of charge; however, some parents 
paid for specific vaccines (e.g., at private clinics or vaccines not included in the government 
program). There were some noted differences between private and government vaccine 
locations, as illustrated by a parent who said that “In private settings there is no guarantee, we 
have belief in government … if any problem comes also we have chance to ask them” (mother, 
24). 
Extensive vaccine programs resulted in vaccine behavior being heavily influenced by health 
professionals. Several parents (n = 8) reported a willingness to do whatever the doctor or health 
worker instructs them: “She [ANM] says if we give the vaccine from childhood onwards then we 
can prevent certain diseases, so that's why we’re prepared to give vaccines to children” (father, 
38). Another father (35) commented that lack of education meant that they relied on the provided 
information: 
We have not studied much and we don't have much knowledge about these things even. The 
doctor gives our treatment; we only accept it. That's all. We don't know what types of medicine 
are given, the only thing we do is we follow according to what were suggested to us to do, that's 
all. 
Little emphasis was reported in helping parents understand the utility of the vaccines or the 
importance of booster vaccines for older children. 
HPV Vaccine Preferences and Acceptability 
Despite low levels of knowledge related to HPV and the associated vaccine, most parents were 
willing to vaccinate their children against HPV, especially with a health worker 
recommendation. Many parents (n = 22) reported acceptance of girls-only vaccination. Others (n 
= 12), however, indicated that the vaccine would only be acceptable if it was given to both girls 
and boys. The gendered behavioral expectations were highlighted by one mother (28): 
Why? Mostly boys do wrong and we don't know where he is going and what habits he has. 
Whereas girls’ parents, at least for a while, we will be back of her tracking what she is doing. So 
in my opinion if the vaccine is given to boys it will be good because he will also get this virus if 
he has bad behavior habits. 
Conversely, one mother (28) discussed vaccination in terms of boys’ rights: 
Parents will not accept, madam. Vaccine should be given to boys also. … Even they have the 
chance of getting this virus, right? First the virus will affect boys, right? So vaccine should be 
given to both boys and girls. 
Preferences for HPV vaccine delivery included injection (n = 7), drops (n = 5), tablets (n = 4), or 
a combination (n = 5). All parents reported that they would vaccinate their children if the 
vaccines were free; 18 parents reported willingness to pay. Primary obstacles to vaccination were 
related to missing work for vaccine appointments and associated costs. Although vaccines were 
free (or low cost) the family still lost daily wages, as noted by one mother (28): 
When we say to them that they need to get children vaccinated, they say that they have work. 
And even sometimes, if the parents show interest, then the government sister will not come on 
time promptly to the village. The parents had to wait all day and lost work for that day and lost 
one day wages because of the government sister's delay. 
Overall, the most common barriers to HPV vaccination were work (n = 12), cost (n = 6), side 
effects (n = 3), education (n = 3), and other (e.g., effectiveness, karma; n = 9). There was little 
concern related to transportation as most of the clinics were nearby or health workers came to the 
village. 
DISCUSSION 
The purpose of the study was to assess parents’ attitudes about HPV vaccine as well as general 
vaccine and STI-related knowledge in a specific region of India. Our results indicated that 
among parents, STI- (with the exception of HIV/AIDS) and HPV-related knowledge were low, 
yet HPV vaccine acceptability was high. Parents acknowledged the importance of vaccines for 
children's health, which likely contributed to positive views of the HPV vaccine. 
Similar to existing research (Basu & Mittal, 2011; Bingham et al., 2009; Dinh et al., 2007; Jacob 
et al., 2010; Kwan et al., 2008; Madhivanan et al., 2009; Sam et al., 2009), parents had not heard 
about HPV and had limited knowledge about cervical cancer. Although the relationship of HPV 
knowledge to vaccine acceptability varies (reviewed in Brewer & Fazekas, 2007; Trim, Nagji, 
Elit, & Roy, 2012), communities continue accepting vaccines with insufficient knowledge. This 
practice suggests that parental knowledge may not be essential for successful programs (Nichter, 
1995); however, public health ethics highlight the need for better informed consent procedures. 
In contrast to results from another study (Krupp et al., 2010), parents indicated that health care 
personnel's recommendations and government endorsement play an integral role in vaccine 
behaviors (Basu & Mittal, 2011). Given the potential role of health providers and government 
officials, understanding their HPV vaccine attitudes should continue to be investigated. 
Furthermore, there have been recent controversies in India over implementation of HPV vaccine 
studies (e.g., adverse event/side effects) resulting in the suspension of these projects (Choudhury 
& John, 2010; Larson, Brocard, & Garnett, 2010). Although the concerns were largely 
unfounded (Choudhury & John, 2010), these unfortunate events highlight the need for Indian 
health authorities and government officials to address people's concerns clearly and quickly to 
dispel fears based on misinformation and focus on improving the informed consent process 
(Larson et al., 2010). 
Current immunization programs in Andhra Pradesh focus on children less than 2 years old. The 
majority of the households in our study reported that their children received at least one of the 
EPI vaccines. This immunization coverage aligns with previous data; less than 5% of children in 
Andhra Pradesh had not received any vaccines at all by 2 years of age (National Family Health 
Survey [NFHS], 2009). Boosters for 5 and 10 year olds are administered opportunistically at the 
primary health center, which may have implications for the addition of HPV vaccines to the 
expanded immunization program, given the later age of administration (9–26 years). While 
parental HPV vaccine acceptability was high, a primary challenge will be vaccinating 
adolescents who have less formal interactions with the health care system compared with 
existing vaccine for younger children. 
The majority of parents reported acceptance of girls-only vaccination; however, some believed 
vaccines should be given to girls and boys. The interest in HPV vaccine for both genders is in 
line with the recent Food and Drug Administration (FDA) approval of vaccination for males in 
the United States and needs to be explored further in Indian contexts as it has important 
implications for reducing HPV and cervical cancer rates. 
Our data highlight parental concerns about vaccine-related side effects (Basu & Mittal, 2011). 
The most common side effects for HPV vaccines are pain at the injection site (local) and 
headaches (systemic; FDA, 2009). Although these side effects are not serious adverse events, 
they may represent concerns for the parents, be the basis for misinformation, and lead to negative 
HPV vaccine attitudes. It is important that personnel provide accurate information about safety 
and side effects to address potential concerns. 
Several other issues were discussed as barriers to HPV vaccine acceptance, including cost, 
missing work and fitting into the existing program (Das et al., 2008; Jacob et al., 2010; 
Madhivanan et al., 2009; Sankaranarayanan 2009; Zimet et al., 2006, 2008). While parents 
expressed apprehension about a vaccine requiring payment, they were also concerned about lost 
daily wages when taking their children to receive immunizations. This may be a contributing 
factor for high dropout rates between the first and third doses for vaccines like DPT and polio 
(Gupta, Gupta, Gupta, Venkatesh, & Lal, 2006) and may be an issue for a multidose HPV 
vaccine. This is an important consideration when designing vaccine programs. Transportation 
was not identified as a barrier to HPV vaccine acceptance because health workers come to the 
villages. While this is how childhood immunizations are delivered, it might not be feasible to 
reach adolescents through the community-based program. If the vaccine is not directly provided 
in the villages, then transportation may become a barrier. The feasibility of incorporating HPV 
vaccines into immunization programs needs to be explored further. 
Although the introduction of the HPV vaccine is expected to reduce cervical cancer rates; there 
continues to be a debate in India about whether prevention resources should concentrate on 
vaccine-based primary prevention or cervical cancer screening programs. Even in the presence of 
a strong health infrastructure and an inexpensive test, low compliance with screening continues 
to be a barrier (Dinshaw et al., 2007; Gravitt et al., 2010; Nene et al., 1996). Screening is still 
essential in cervical cancer prevention as the population impact of a vaccine-based program will 
not be apparent for at least 15–20 years and the vaccine is not completely protective against 
cervical cancer (Basu & Chowdhury, 2009). Women fear cancer diagnosis and frequently neglect 
their own health to take care of the family (Basu et al., 2006; Gravitt et al., 2010). Therefore, 
mobilizing mothers to vaccinate their daughters to protect against cancer may be more effective. 
A multipronged approach with comprehensive education messages that promote HPV 
vaccination for adolescents and increase awareness of cervical cancer screening may be the most 
efficient use of resources, especially in low resource settings. 
Individual interviews helped delineate personal beliefs about vaccination, but the small sample 
size and demographics of the participants (e.g., majority Hindu compared with Muslim) may not 
represent the whole community's views. Potential religious differences and fathers’ influences on 
vaccine acceptance should be explored more fully. The relationship of HPV vaccine 
acceptability to actual vaccine uptake and coverage may depend on a variety of factors such as 
mandatory vaccinations and vaccine delivery. HPV vaccine acceptance after programs are 
implemented needs to be evaluated. 
Current HPV vaccine acceptability research has primarily been conducted in the United States, 
Europe, and some Asian countries (Bingham et al., 2009; Brewer & Fazekas, 2007; Dinh et al., 
2007; Kwan et al., 2008; Zimet et al., 2006, 2008). Given the cervical cancer burden and the 
population density and diversity in India (and other developing countries), it is essential to get a 
better understanding of HPV vaccine acceptability. Programs that build on the strong 
infrastructure of the existing immunization program address parental concerns about vaccine 
safety and side effects, incorporate positive recommendation from health workers, have 
governmental policy support, and have efforts to minimize cost of HPV vaccine are essential for 
the successful implementation and uptake of the HPV vaccine in India. The vaccine delivery 
mode, number of doses, and other logistical concerns may affect HPV vaccine acceptance and 
utilization. Although extensive educational campaigns may not be extremely helpful, ethically, 
accurate information about HPV vaccines and cervical cancer should be provided. Such 
education programs may allow for development of a dialogue around the benefits of early 
protection from cervical cancer, thereby enhancing multipronged cervical cancer prevention. 
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